Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Lantus-(Cartridge) (02251930), Lantus Solostar (02294338). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Insulin glargine
5 general benefit · 1 Limited Use
Lantus-(Vial) · DIN 02245689 · 100U/mL · injection solution-10mL vial
Limited Use, Reason for Use code 644 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 644 required
Write on scriptReason for Use code 644 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 644
Reason for Use code 644
Patient requires insulin therapy and is unable to use the insulin pen.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Lantus-(Vial) · DIN 02245689
Manufacturer: Sanofi Aventis Pharma; listing date 2008-12-03
Health Canada: Marketed since 2007-10-23 · brand LANTUS · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 100 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordLantus-(Vial): Formulary list price $61.69 per unit (the source does not state the unit; exact figure $61.6900). What the ministry pays, not the patient.
Ministry pays: $61.6900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245689)
Source record
DIN 02245689: Lantus-(Vial)
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682014009; group id 781; item number 1901; lccId 00367; manufacturer id SAV
Source form: Inj Sol-10mL Vial Pk; strength: 100U/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $61.6900; ministry $61.6900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245689
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69790
Shortage status: resolved shortage (ended September 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245689
Shortage record checked October 6, 2026
Semglee · DIN 02526441 · 100U/mL · injection solution-3mL pre-filled pen
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Semglee · DIN 02526441
Manufacturer: Bicon SDN. BHD.; listing date 2022-12-21
Health Canada: Marketed since 2024-07-12 · brand SEMGLEE · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 100 UNIT/ML · company Biocon sdn.bhd · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordSemglee: Formulary list price $12.77 per unit (the source does not state the unit; exact figure $12.7668). What the ministry pays, not the patient.
Ministry pays: $12.7668 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02526441)
Source record
DIN 02526441: Semglee
Raw flags: insOH=Y, sec3=Y
Item: 682014019; group id 782; item number 1902; lccId None; manufacturer id BSB
Source form: Inj Sol-3mL Pref Pen; strength: 100U/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $12.7668; ministry $12.7668
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02526441
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101554
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02526441
Shortage record checked October 6, 2026
Basaglar · DIN 02444844 · 100U/mL · injection solution-Cartridge 5x3mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Basaglar · DIN 02444844
Manufacturer: Eli Lilly Canada Inc.; listing date 2017-08-30
Health Canada: Marketed since 2015-12-18 · brand BASAGLAR · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 100 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordBasaglar: Formulary list price $84.70 per unit (the source does not state the unit; exact figure $84.7000). What the ministry pays, not the patient.
Ministry pays: $84.7000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444844)
Source record
DIN 02444844: Basaglar
Raw flags: insOH=Y, sec3=Y
Item: 682014012; group id 782; item number 1904; lccId None; manufacturer id LIL
Source form: Inj Sol-Cartridge 5x3mL Pk; strength: 100U/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $84.7000; ministry $84.7000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444844
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93005
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444844
Shortage record checked October 6, 2026
Basaglar · DIN 02461528 · 100U/mL · injection solution-KwikPen (80U) pre-filled pen 5x3mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Basaglar · DIN 02461528
Manufacturer: Eli Lilly Canada Inc.; listing date 2019-03-28
Health Canada: Marketed since 2017-08-18 · brand BASAGLAR · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 100 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordBasaglar: Formulary list price $84.70 per unit (the source does not state the unit; exact figure $84.7000). What the ministry pays, not the patient.
Ministry pays: $84.7000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461528)
Source record
DIN 02461528: Basaglar
Raw flags: insOH=Y, sec3=Y
Item: 682014017; group id 782; item number 1905; lccId None; manufacturer id LIL
Source form: Inj Sol-KwikPen (80U) Pref Pen 5x3mL Pk; strength: 100U/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $84.7000; ministry $84.7000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461528
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94916
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461528
Shortage record checked October 6, 2026
TOUJEO SoloSTAR · DIN 02441829 · 300U/mL · injection solution-1.5mL pre-filled pen
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
TOUJEO SoloSTAR · DIN 02441829
Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2018-09-27
Health Canada: Marketed since 2015-07-15 · brand TOUJEO SOLOSTAR · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 300 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordTOUJEO SoloSTAR: Formulary list price $26.43 per unit (the source does not state the unit; exact figure $26.4333). What the ministry pays, not the patient.
Ministry pays: $26.4333 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02441829)
Source record
DIN 02441829: TOUJEO SoloSTAR
Raw flags: insOH=Y, sec3=Y
Item: 682014014; group id 780; item number 1900; lccId None; manufacturer id SAC
Source form: Inj Sol-1.5mL Pref Pen; strength: 300U/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $26.4333; ministry $26.4333
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02441829
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92621
Shortage status: active shortage (reported August 31, 2026, last updated September 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441829
Shortage record checked October 6, 2026
Toujeo DoubleSTAR · DIN 02493373 · 300U/mL · injection solution-3mL pre-filled pen
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Toujeo DoubleSTAR · DIN 02493373
Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2020-09-30
Health Canada: Marketed since 2020-02-04 · brand TOUJEO DOUBLESTAR · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 300 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordToujeo DoubleSTAR: Formulary list price $52.87 per unit (the source does not state the unit; exact figure $52.8666). What the ministry pays, not the patient.
Ministry pays: $52.8666 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493373)
Source record
DIN 02493373: Toujeo DoubleSTAR
Raw flags: insOH=Y, sec3=Y
Item: 682014018; group id 782; item number 1903; lccId None; manufacturer id SAC
Source form: Inj Sol-3mL Pref Pen; strength: 300U/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $52.8666; ministry $52.8666
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493373
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98339
Shortage status: resolved shortage (ended August 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02493373
Shortage record checked October 6, 2026
Other products in the same Health Canada class (A10AE): coverage varies; not interchangeable
- Insulin degludec (Tresiba): general benefit
- Insulin detemir (Levemir Penfill): general benefit
Insulin glargine & lixisenatide
All injection strengths: general benefit
Soliqua · DIN 02478293 · 100U/mL & 33 mcg/mL · injection solution-pre-filled pen 5x3mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Soliqua · DIN 02478293
Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2019-12-20
Health Canada: Marketed since 2018-09-12 · brand SOLIQUA · ATC A10AE54 INSULIN GLARGINE AND LIXISENATIDE, A10AE54 INSULIN GLARGINE AND LIXISENATIDE · form Solution · route Subcutaneous · ingredients LIXISENATIDE 33 MCG/ML, INSULIN GLARGINE 100 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSoliqua: Formulary list price $206.60 per unit (the source does not state the unit; exact figure $206.6000). What the ministry pays, not the patient.
Ministry pays: $206.6000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02478293)
Source record
DIN 02478293: Soliqua
Raw flags: insOH=Y, sec3=Y
Item: 682006005; group id 758; item number 1863; lccId None; manufacturer id SAC
Source form: Inj Sol-Pref Pen 5x3mL Pk; strength: 100U/mL & 33mcg/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $206.6000; ministry $206.6000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02478293
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96906
Therapeutic Notes (formulary)
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) in combination with metformin.
Shortage status: resolved shortage (ended August 3, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02478293
Shortage record checked October 6, 2026
Other products in the same Health Canada class (A10AE): coverage varies; not interchangeable
- Insulin degludec (Tresiba): general benefit
- Insulin detemir (Levemir Penfill): general benefit
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (68:20:06 Incretin Mimetics) and how they are covered
Matched class: 68:20:06 Incretin Mimetics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
No displayed product is listed as a general benefit in this extract. Check its listing requirements below.
68:20:06 Incretin Mimetics
· 13 products ·
Limited Use, codes 667 (2),
Limited Use, codes 666 (2),
Limited Use, codes 665 (3),
Limited Use, codes 738 (1),
Limited Use, codes 662 (1),
Limited Use, codes 739 (1),
Limited Use, codes 663 (1),
Limited Use, codes 740 (1),
Limited Use, codes 664 (1) · strengths: 0.68mg/mL, 1.34mg/mL, 1.5mg, 3mg, 4mg, 7mg, 9mg, 14mg · Inj Sol - Pref Pen 3mL Pk, Inj Sol-Pref Pen 1.5mL Pk, Inj Sol-Pref Pen 3mL Pk, Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:06
Full class listing
Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed)
Other drugs in the same formulary class (68:20:14 Insulins (Long Acting)) and how they are covered
Matched class: 68:20:14 Insulins (Long Acting)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: INSULIN DEGLUDEC, INSULIN DETEMIR
68:20:14 Insulins (Long Acting)
· 3 products · General benefit · strengths: 100U/mL, 200U/mL · Inj Sol-3X5mL Cart Pk, Inj Sol-Flextouch Pref Pen 3x3mL Pk, Inj Sol-Flextouch Pref Pen 5x3mL Pk
· 2 products · General benefit · strengths: 100U/mL · Inj Sol-5x3mL Pk, Inj Sol-Pref Disp Pen 5X3mL Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:14
Full class listing
Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:16 Insulins (Pre-Mixed)
Same formulary class, not same indication: class membership alone does not establish equivalent uses.